This systematic review with embedded meta-analysis aimed to evaluate the clinical utility of circulating tumor DNA (ctDNA) in lung cancer. After screening and review of the Embase database search, 111 studies from 2015 to 2020 demonstrated ctDNA's value in prognostication/monitoring disease progression, mainly in patients with advanced/metastatic disease and non-small cell lung cancer. ctDNA positivity/detection at any time point was associated with shorter progression-free survival and overall survival, whereas ctDNA clearance/decrease during treatment was associated with a lower risk of progression and death. Validating these findings and addressing challenges regarding ctDNA testing integration into clinical practice will require further research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07357907.2023.2220820 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Awake thoracic surgery for lung cancer treatment: where we are and future perspectives-our experience and review of literature.
J Cardiothorac Surg
January 2025
Thoracic Surgery Unit, Careggi University Hospital, Largo Brambilla, 1, 50134, Florence, Italy.
Background: Lung cancer is the first cause of cancer-related death. Awake lung resection is a new frontier of the concept of minimally invasive surgery. Our purpose is to demonstrate the feasibility of this technique for lobar and sublobar lung resection in NSCLC patients.
View Article and Find Full Text PDFBackground: Metabolic pathways are known to significantly impact the development and advancement of lung cancer. This study sought to establish a signature related to butyrate metabolism that is specifically linked to lung adenocarcinoma (LUAD).
Methods: For the purpose of identifying butyrate metabolism-related differentially expressed genes (BMR-DEGs) in the TCGA-LUAD dataset, we introduced transcriptome data.
LncRNA MANCR is downregulated in non-small cell lung cancer and predicts poor survival.
Discov Oncol
January 2025
Spinal Surgery Department, the Fourth People's Hospital of Jinan, No.50 Normal Road, Tianqiao District, Jinan, 250031, Shandong, China.
Background: It is known that genomic instability contributes to cancer development. Mitotically associated long non-coding RNA (MANCR) has been reported to promote genomic stability, suggesting its involvement in cancers. Therefore, this study was conducted to investigate the role of MANCR in non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFIntegrated bioinformatics and experimental analysis of CHAF1B as a novel biomarker and immunotherapy target in LUAD.
Discov Oncol
January 2025
The School Public Health, Fujian Medical University, Fuzhou, 350122, Fujian, China.
The prognosis and treatment efficacy of lung adenocarcinoma (LUAD), a disease with a high incidence, remains unsatisfactory. Identifying new biomarkers and therapeutic targets for LUAD is essential. Chromosomal assembly factor 1B (CHAF1B), a p60 component of the CAF-1 complex, is closely linked to tumor incidence and cell proliferation.
View Article and Find Full Text PDFInvestigating causal relationships between plasma proteins and lung adenocarcinoma: result from proteomics and Mendelian randomization study.
Discov Oncol
January 2025
Respiratory Department, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua, 310053, Zhejiang, China.
Background: Plasma proteins contribute to the identification, diagnosis, and prognosis of human illnesses, which may be conducive to understanding the molecular mechanism and diagnosis of Lung adenocarcinoma (LUAD).
Methods: We collected plasma samples from 28 healthy individuals (H) and 56 LUAD patients and analyzed them using LC-MS/MS-based proteomics to determine differential expression plasma proteins (DEPPs). Then, the DEPPs were subjected to a two-sample Mendelian randomization (MR) study based on an "Inverse variance weighted (IVW)" approach to investigate the causal relationships between DEPPs and LUAD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!